How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

65,440 results for

Type 1 Diabetes Mellitus

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Evaluating a dietary pattern in adolescents with type 1 diabetes mellitus: The dash-d approach. (PubMed)

Evaluating a dietary pattern in adolescents with type 1 diabetes mellitus: The dash-d approach. Adolescents with type 1 diabetes (T1DM) must consider multiple factors in diet planning, including glycemic control and cardiovascular disease prevention, while ensuring adequate nutrition for growth. We examined diet composition, quality, and compliance for two dietary patterns - the traditional Dietary Approaches to Stop Hypertension (DASH) and a modified version of DASH in this population.Two (...) feeding studies were conducted. First, adolescents with T1DM consumed their usual diet for 3 days followed by traditional DASH for 6 days. Next, DASH menus were adjusted to align with T1DM nutrition guidelines, and this modified DASH for Diabetes (DASH-D) was tested on a new group of adolescents with T1DM for 6 days, following 3 days of usual diet. Usual diet was measured via 24-hr dietary recalls. Dietary composition of DASH-D was compared to DASH and usual diet. Eighteen adolescents (9/group

2019 Diabetes management (London, England) Controlled trial quality: uncertain

122. Clinical efficacy of Professional Continuous Glucose Monitoring in improving glycemic control among children with Type 1 Diabetes Mellitus: An Open-label Randomized Control Trial. (PubMed)

Clinical efficacy of Professional Continuous Glucose Monitoring in improving glycemic control among children with Type 1 Diabetes Mellitus: An Open-label Randomized Control Trial. Frequent self-monitoring of blood glucose (SMBG) is the only accurate method available for insulin dose titration in patients with T1DM. Professional continuous glucose monitoring (p-CGM) is blinded recording of glucose trends over 5-7 days and helps physicians to guide insulin titration to patient. This study

2019 Scientific reports Controlled trial quality: uncertain

123. Demystifying the Pizza Bolus: The Effect of Dough Fermentation on Glycemic Response-A Sensor-Augmented Pump Intervention Trial in Children with Type 1 Diabetes Mellitus. (PubMed)

Demystifying the Pizza Bolus: The Effect of Dough Fermentation on Glycemic Response-A Sensor-Augmented Pump Intervention Trial in Children with Type 1 Diabetes Mellitus. Background: Glycemia following pizza consumption is typically managed with a dual-wave insulin bolus. This study evaluated the effect of a simple bolus on glycemia following consumption of traditionally prepared pizzas with long (24 h) or short (8 h) dough fermentation periods. Research Design and Methods: On two separate (...) evenings, children with type 1 diabetes (n = 38) receiving sensor-integrated pump therapy consumed traditionally prepared pizza with either short (pizza A) or long (pizza B) dough fermentation, and blood glucose was monitored over 11 h. A simple insulin bolus was administered 15 min preprandially. The carbohydrate and amino acid contents of the two types of pizza were analyzed by liquid chromatography and high-resolution mass spectrometry (LC-HRMS). Results: The mean (±standard deviation) time in range

2019 Diabetes technology & therapeutics Controlled trial quality: uncertain

124. Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study. (PubMed)

Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study. Empagliflozin, a highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, improves glycaemic control in patients with type 2 diabetes mellitus (T2DM) by inducing urinary glucose excretion. Combination therapy with empagliflozin and glucagon-like peptide-1 (GLP-1) receptor agonists (...) had not previously been assessed, so we investigated the safety, tolerability and efficacy of empagliflozin as an add-on therapy to liraglutide, a GLP-1 receptor agonist.This was a randomised, double-blind, parallel-group phase 4 trial of empagliflozin (10 mg or 25 mg) for 52 weeks as an add-on therapy to liraglutide (0.9 mg/day) in Japanese patients with T2DM insufficiently controlled by liraglutide alone.59.4% (19/32) and 66.7% (22/33) of patients in the empagliflozin 10 mg and 25 mg groups

2019 Diabetes therapy : research, treatment and education of diabetes and related disorders Controlled trial quality: uncertain

125. Comparison of adjunctive therapy with metformin and acarbose in patients with Type-1 diabetes mellitus. (PubMed)

Comparison of adjunctive therapy with metformin and acarbose in patients with Type-1 diabetes mellitus. All the aforementioned data have stimulated interest in studying other potential therapies for T1DM including noninsulin pharmacological therapies. The present study attempts to investigate the effect of adjunctive therapy with metformin and acarbose in patients with Type-1 diabetes mellitus.In a single-center, placebo-controlled study (IRCT201102165844N1) we compared the results of two (...) clinical trials conducted in two different time periods on 40 patients with Type-1 diabetes mellitus. In the first section, metformin was given to the subjects. After six months, metformin was replaced with acarbose in the therapeutic regimen. In both studies, subjects were checked for their BMI, FBS, HbA1C, TGs, Cholesterol, LDL, HDL, 2hpp, unit of NPH and regular insulin variations.Placebo-controlled evaluation of selected factors has showna significant decrease in FBS and TG levels in the metformin

2019 Pakistan Journal Of Medical Sciences Controlled trial quality: uncertain

126. Efficacy and safety of a rosehip seed oil extract in the prevention and treatment of skin lesions in the hands of patients with type 1 diabetes mellitus caused by finger prick blood glucose monitoring; a randomized, open-label, controlled clinical trial. (PubMed)

Efficacy and safety of a rosehip seed oil extract in the prevention and treatment of skin lesions in the hands of patients with type 1 diabetes mellitus caused by finger prick blood glucose monitoring; a randomized, open-label, controlled clinical trial. This study was intended to assess the efficacy and safety of a rosehip seed oil (RHO) extract in the prevention and treatment of skin lesions in the hands of patients with type 1 diabetes mellitus (T1DM) caused by finger prick blood glucose

2019 Endocrinologia, diabetes y nutricion Controlled trial quality: uncertain

127. The Effects of Adiponectin and Adiponectin Receptor 1 Levels on Macrovascular Complications Among Patients with Type 2 Diabetes Mellitus. (PubMed)

The Effects of Adiponectin and Adiponectin Receptor 1 Levels on Macrovascular Complications Among Patients with Type 2 Diabetes Mellitus. The present study aimed to investigate the serum levels of adiponectin (APN) and adiponectin receptor 1 (AdipoR1) in patients with type 2 diabetes mellitus (T2DM) combined with macrovascular complications (MVC), as well as their correlation with clinical parameters.A total of 60 T2DM patients were divided into 2 groups according to the presence of MVC: T2DM

2019 Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology Controlled trial quality: uncertain

128. Type 1 Diabetes Mellitus and Cardiovascular Disease: A Scientific Statement From the American Heart Association and American Diabetes Association

Type 1 Diabetes Mellitus and Cardiovascular Disease: A Scientific Statement From the American Heart Association and American Diabetes Association Type 1 Diabetes Mellitus and Cardiovascular Disease | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January 2019 This site uses cookies (...) . By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Type 1 Diabetes Mellitus and Cardiovascular Disease A Scientific Statement From the American Heart Association and American Diabetes Association , MD, MPH , MD, MS , MD , MD, MPH , MD, MHS , MD , MD, MSCE , MD , MD , MD, MMedSci , and MD MD, FAHA Sarah D. de Ferranti , Ian H. de Boer , Vivian Fonseca , Caroline S. Fox *The input provided by Dr. Fox is from her own perspective

2014 American Heart Association

129. Statement on prescribing Freestyle Libre flash glucose monitoring system for type 1 and type 2 diabetes

requiring multiple daily insulin dosing for Type 1 and Type 2 diabetes mellitus. The current evidence, however, does not support routine adoption. The use of Freestyle Libre may be considered as an alternative to finger-prick selfmonitoring of blood glucose in clinical circumstances where multiple testing (eight or more times per day) is required. Why was this topic appraised? HTW previously facilitated publication of an Interim Statement on the prescribing of FreeStyle Libre flash glucose monitoring (...) Statement on prescribing Freestyle Libre flash glucose monitoring system for type 1 and type 2 diabetes FreeStyle Libre flash glucose monitoring - Health Technology Wales > FreeStyle Libre flash glucose monitoring FreeStyle Libre flash glucose monitoring Topic Status Incomplete FreeStyle Libre flash glucose monitoring for the management of type 1 or type 2 diabetes. Outcome of the appraisal Freestyle Libre shows promise for detecting and guiding the correction of hypoglycaemia in patients

2018 Health Technology Wales

130. In-hospital, short-term and long-term adverse clinical outcomes observed in patients with type 2 diabetes mellitus vs non-diabetes mellitus following percutaneous coronary intervention: A meta-analysis including 139,774 patients. (PubMed)

In-hospital, short-term and long-term adverse clinical outcomes observed in patients with type 2 diabetes mellitus vs non-diabetes mellitus following percutaneous coronary intervention: A meta-analysis including 139,774 patients. Several studies have shown that patients with type 2 diabetes mellitus (T2DM) have worse clinical outcomes in comparison to patients without diabetes mellitus (DM) following Percutaneous Coronary Intervention (PCI). However, the adverse clinical outcomes were (...) manifested.According to this meta-analysis including a total number of 139,774 patients, following PCI, those patients with T2DM suffered more in-hospital, short as well as long-term adverse outcomes as reported by most of the Randomized Controlled Trials and Observational studies, compared to those patients without diabetes mellitus.

2019 Medicine

131. Risk of Mortality and Hospitalization After Post-Pancreatitis Diabetes Mellitus vs Type 2 Diabetes Mellitus: A Population-Based Matched Cohort Study. (PubMed)

Risk of Mortality and Hospitalization After Post-Pancreatitis Diabetes Mellitus vs Type 2 Diabetes Mellitus: A Population-Based Matched Cohort Study. To investigate the risk of mortality and hospitalization in individuals with post-pancreatitis diabetes mellitus (PPDM) compared with those with type 2 diabetes mellitus (T2DM).Using nationwide hospital discharge data on pancreatitis and diabetes in New Zealand (n = 231,943), a total of 959 individuals with PPDM were identified. For each

2019 American Journal of Gastroenterology

132. EARLY MICROVASCULAR AND NEURAL CHANGES IN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES MELLITUS WITHOUT CLINICAL SIGNS OF DIABETIC RETINOPATHY. (PubMed)

EARLY MICROVASCULAR AND NEURAL CHANGES IN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES MELLITUS WITHOUT CLINICAL SIGNS OF DIABETIC RETINOPATHY. To assess and compare early modifications in inner retinal layer thickness and optical coherence tomography angiography parameters in patients with diabetes mellitus (DM) Types 1 and 2 without clinical signs of diabetic retinopathy.Ninety eyes of 90 subjects (24 Type 1 DM, 36 Type 2 DM, and 30 healthy controls) were prospectively evaluated with spectral (...) of the capillaries was higher in DM Type 1 versus controls in both SCP and DCP (P < 0.01 for all); and in DM Type 2 versus controls only in DCP (P = 0.007). Perifoveal capillary loss in SCP and inner retinal layer thickness had the highest correlation in both DM types.There are specific neural and microvascular modifications even before clinical signs of diabetic retinopathy in DM Types 1 and 2. Perifoveal capillary loss in the SCP is highly correlated with inner retinal layer. These data may help

Full Text available with Trip Pro

2017 Retina

133. Randomized clinical trial: Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus

Randomized clinical trial: Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see (...) our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus Article

2016 Evidence-Based Medicine (Requires free registration)

134. Type 1 diabetes

Type 1 diabetes Type 1 diabetes - Symptoms, diagnosis and treatment | BMJ Best Practice   Search  Type 1 diabetes Last reviewed: February 2019 Last updated: March 2018 Summary Type 1 diabetes mellitus is a metabolic disorder characterised by hyperglycaemia due to absolute insulin deficiency. Patients most often present with a few days or weeks of polyuria, polydipsia, weight loss, and weakness. Some patients may present with diabetic ketoacidosis. Intensive glycaemic control has been shown (...) to decrease the incidence of microvascular and macrovascular complications. Microvascular complications include retinopathy, nephropathy, and neuropathy. Macrovascular complications include coronary artery, cerebrovascular, and peripheral vascular disease. Definition Type 1 diabetes mellitus is a metabolic disorder characterised by hyperglycaemia due to absolute insulin deficiency. The condition develops due to destruction of pancreatic beta cells, mostly by immune-mediated mechanisms. In some patients

2018 BMJ Best Practice

135. Excess mortality and life expectancy of individuals with type 1 diabetes: a rapid review

: Diabetes Mellitus, Type 1; Life expectancy; Mortality; Survival NLM Classification: WK810 Language: English Format: Adobe® PDF™ (A4) Legal depot: D/2019/10.273/37 ISSN: 2466-6459 Copyright: KCE reports are published under a “by/nc/nd” Creative Commons Licence http://kce.fgov.be/content/about-copyrights-for-kce-publications. How to refer to this document? Louwagie P, De Laet C, Roberfroid D. Excess mortality and life expectancy of individuals with type 1 diabetes: a rapid review. Health Services (...) Research (HSR) Brussels: Belgian Health Care Knowledge Centre (KCE). 2019. KCE Reports 314. D/2019/10.273/37. This document is available on the website of the Belgian Health Care Knowledge Centre. KCE Report 314 Excess mortality and life expectancy of individuals with type 1 diabetes 1 ? TABLE OF CONTENTS LIST OF TABLES 4 LIST OF ABBREVIATIONS 5 ? SCIENTIFIC REPORT 7 1 BACKGROUND 7 1.1. CONTEXT 7 1.2. RESEARCH QUESTION 7 1.3. TYPE 1 DIABETES MELLITUS 7 1.4. GENERAL CLINICAL CONSIDERATIONS AND CONTEXT 8

2019 Belgian Health Care Knowledge Centre

136. Risk factors for development and progression of diabetic retinopathy in Dutch patients with type 1 diabetes mellitus. (PubMed)

Risk factors for development and progression of diabetic retinopathy in Dutch patients with type 1 diabetes mellitus. To investigate risk factors for the development and progression of diabetic retinopathy (DR) and long-term visual outcomes in Dutch patients with type 1 diabetes mellitus (T1DM).Cumulative incidences were calculated for DR, vision-threatening DR (VTDR), defined as (pre)proliferative DR and diabetic macular oedema, and best-corrected visual acuity (BCVA) <0.5 and <0.3 at the most (...) recent eye examination. The following factors were assessed: duration of diabetes, age of onset of T1DM, gender, mean HbA1c, HbA1c variability (defined as coefficient of variation of five separate HbA1c measurements), mean arterial blood pressure, body mass index, albuminuria and lipid profile. We used multivariable Cox regression models to identify factors associated with DR development and progression to VTDR.We found 25-year cumulative incidences of 63% for DR, 21% for VTDR, 2% for BCVA <0.5

Full Text available with Trip Pro

2018 Acta ophthalmologica

137. Worse Metabolic Control and Dynamics of Weight Status in Adolescent Girls Point to Eating Disorders in the First Years after Manifestation of Type 1 Diabetes Mellitus: Findings from the Diabetes Patienten Verlaufsdokumentation Registry. (PubMed)

Worse Metabolic Control and Dynamics of Weight Status in Adolescent Girls Point to Eating Disorders in the First Years after Manifestation of Type 1 Diabetes Mellitus: Findings from the Diabetes Patienten Verlaufsdokumentation Registry. To assess indications of eating disorders in girls with type 1 diabetes mellitus (T1DM).In total 31 556 girls aged >6 months and <23 years of age with T1DM from the Diabetes Patienten Verlaufsdokumentation (DPV) cohort were analyzed including 155 (0.49%) girls (...) with anorexia nervosa, 85 (0.27%) girls with bulimia nervosa, 45 (0.14%) girls with binge eating disorder, and 229 (0.73%) girls with eating disorders not otherwise specified. Patient characteristics, weight changes, numbers of patients with severe hypoglycemia and diabetic ketoacidosis (DKA), changes of glycosylated hemoglobin A1c (HbA1c) levels, use of pumps, and prevalence of celiac disease and autoimmune thyroiditis were compared between girls with and without eating disorders. Multiple logistic

2018 Journal of Pediatrics

138. DETERMINING THE EFFECT OF DIABETES DURATION ON RETINAL AND CHOROIDAL THICKNESSES IN CHILDREN WITH TYPE 1 DIABETES MELLITUS. (PubMed)

DETERMINING THE EFFECT OF DIABETES DURATION ON RETINAL AND CHOROIDAL THICKNESSES IN CHILDREN WITH TYPE 1 DIABETES MELLITUS. Determining the effect of diabetes mellitus duration on retinal and choroidal thicknesses in children with Type 1 diabetes mellitus (T1DM).Children (aged 6-18 years) with Type 1 diabetes and no diabetic retinopathy and age-matched controls were examined using Topcon spectral domain optical coherence tomography. Choroidal thickness and retinal thickness in macula area were (...) measured. The study group was divided into 3 subgroups depending on diabetes mellitus duration-Group 1: <5 years (n = 52), Group 2: 5 to 10 years (n = 39), and Group 3: >10 years (n = 30).One hundred and twenty-one diabetic children and 32 controls were included. The central choroidal thickness increased from 305.5 μm (SD: 61.7 μm) in the control group to 309.2 μm (SD: 70.1 μm) in Group 1, 315.2 μm (SD: 64.3 μm) in Group 2, and 367.4 μm (SD: 66.0 μm) in Group 3. Group 3 differed significantly from

2018 Retina

139. Association of a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13 polymorphisms with severity of coronary stenosis in type 2 diabetes mellitus (PubMed)

Association of a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13 polymorphisms with severity of coronary stenosis in type 2 diabetes mellitus The imbalance of von Willebrand factor (vWF) and a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13 (ADAMTS13) has been associated with atherosclerosis progression. A high level of vWF which regulates thrombus formation is associated with diabetes mellitus (DM), and some ADAMTS13 and vWF

Full Text available with Trip Pro

2018 Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences

140. Macular choroidal thickness in pregnant women with type 1, type 2 and gestational diabetes mellitus measured by spectral-domain optical coherence tomography (PubMed)

Macular choroidal thickness in pregnant women with type 1, type 2 and gestational diabetes mellitus measured by spectral-domain optical coherence tomography To analyze choroidal thickness (CT) of pregnant women with type 1 diabetes mellitus (DM), type 2 DM and gestational diabetes mellitus (GDM) using spectral-domain optical coherence tomography.This cross-sectional study included 144 eyes of 72 pregnant women in the third trimester divided into four groups: 27 non-diabetic pregnant women; 15 (...) pregnant women with GDM; 16 with type 2 DM and 14 with type 1 DM. CT was measured using optical coherence tomography at ten different locations. We also analyzed possible confounding factors, such as gestational age, glycosylated hemoglobin, time from DM diagnosis, hypertension and severity of diabetic retinopathy.The comparison between the four groups showed a thinner choroid in patients with type 1 DM in all locations, with statistical significance in subfoveal and temporal measurements. When

Full Text available with Trip Pro

2018 Clinical ophthalmology (Auckland, N.Z.)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>